Table 3.
Management and outcome at last follow-up
| Characteristic | Kidney (+) MCV | Essential MCV | Primary Sjögren Syndrome | Hematologic malignancy | P Value |
|---|---|---|---|---|---|
| Follow-up (months), mean±SD | 49.9±45.5 | 49.3±40.6 | 64.8±63.6 | 39.2±33.8 | 0.57 |
| Relapses, n (%) | 32 (42.7) | 16 (45.7) | 10 (58.8) | 6 (26.1) | 0.10 |
| Delay to 1st relapse (months), mean±SD | 28.2±19.4 | 19.6±10.7 | 39±24.7 | 32.3±18.9 | 0.19 |
| Renal relapse, n (%) | 24 (75) | 13 (81.3) | 8 (80) | 3 (50) | 0.29 |
| Administered treatments | |||||
| Steroids alone, n (%) | 12 (15.8) | 11 (30.6) | 1 (5.9) | 0 (0) | 0.003 |
| RTX + Steroids, n (%) | 20 (26.3) | 10 (27.8) | 3 (17.7) | 7 (30.4) | 0.64 |
| CYC + Steroids, n (%) | 20 (26.3) | 7 (19.4) | 7 (41.2) | 6 (26.1) | 0.25 |
| CYC + RTX + Steroids, n (%) | 21 (27.6) | 6 (16.7) | 6 (35.3) | 9 (39.1) | 0.12 |
| Other treatment, n (%) | 3 (3.95) | 2 (5.6) | 0 (0) | 1 (4.4) | 0.62 |
| Plasma exchanges, n (%) | 25 (32.9) | 8 (22.2) | 10 (58.8) | 7 (30.4) | 0.03 |
| Renal parameters | |||||
| Proteinuria >0.5 g/d, n (%) | 12 (19) | 5 (17.2) | 3 (21.4) | 4 (20) | 0.94 |
| Hematuria, n (%) | 18 (28.6) | 7 (24.1) | 6 (42.9) | 5 (25) | 0.41 |
| GFRLFup, mean±SD | 50.2±26.1 | 48.3±29.3 | 48.1±23 | 55±23.1 | 0.57 |
| <60 ml/min per 1.73 m2, n (%) | 45 (57.7) | 22 (57.9) | 11 (64.7) | 12 (52.2) | 0.73 |
| <30 ml/min per 1.73 m2, n (%) | 20 (25.6) | 13 (34.2) | 3 (17.6) | 4 (17.4) | 0.24 |
| <15 ml/min per 1.73 m2, n (%) | 7 (9) | 5 (13.2) | 2 (11.8) | 0 (0) | 0.20 |
| Renal outcome | 0.12 | ||||
| NR, n (%) | 21 (26.9) | 11 (28.9) | 5 (29.4) | 5 (21.7) | |
| PR, n (%) | 18 (23.1) | 10 (26.3) | 3 (17.6) | 5 (21.7) | |
| CR, n (%) | 39 (50) | 17 (44.7) | 9 (52.9) | 13 (56.5) | |
| Clinical outcome | 0.21 | ||||
| NR, n (%) | 16 (17.9) | 6 (15.8) | 4 (23.5) | 4 (17.4) | |
| PR, n (%) | 18 (23.1) | 12 (31.6) | 3 (17.6) | 3 (13) | |
| CR, n (%) | 46 (59) | 20 (52.6) | 10 (58.8) | 16 (69.6) | |
| New-onset hematologic malignancy, n (%) | 5 (8.9) | 2 (5.6) | 3 (16.7) | — | 0.37 |
| Severe Infections, n (%) | 23 (29.1) | 12 (31.6) | 4 (22.2) | 7 (30.4) | 0.76 |
| Death, n (%) | 19 (24) | 9 (23.7) | 5 (27.8) | 5 (21.7) | 0.90 |
RTX, rituximab; CYC, cyclophosphamide; GFRLFup, glomerular filtration rate at last follow-up expressed in ml/min per1.73 m2; NR, nonresponder; PR, partial remission; CR, complete remission.